Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/99366
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahmadian, A. | - |
dc.contributor.author | Brogan, A. | - |
dc.contributor.author | Berman, J. | - |
dc.contributor.author | Sverdlov, A. | - |
dc.contributor.author | Mercier, G. | - |
dc.contributor.author | Mazzini, M. | - |
dc.contributor.author | Govender, P. | - |
dc.contributor.author | Ruberg, F. | - |
dc.contributor.author | Miller, E. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Journal of Nuclear Cardiology, 2014; 21(5):925-939 | - |
dc.identifier.issn | 1071-3581 | - |
dc.identifier.issn | 1532-6551 | - |
dc.identifier.uri | http://hdl.handle.net/2440/99366 | - |
dc.description.abstract | Background: FDG PET/CT with myocardial perfusion imaging is a useful method for evaluating cardiac sarcoidosis (CS), but interpretation is not standardized. We developed a method for quantification of cardiac FDG PET/CT and evaluated its relationship to conventional interpretation, perfusion defects, clinical events, and immunosuppressive treatment. Methods and Results: FDG PET/CT with MPI studies performed for CS (n = 38) were retrospectively compared to negative control studies acquired for oncologic indications (n = 10). Quantitative measures of FDG volume-intensity (Cardiac Metabolic Activity, CMA) was performed using standardized uptake values (SUVs). CMA (477.7 ± 909 vs 0.55 ± 2.1 vs 0.3 ± 0.3 g glucose, P = .02) was significantly greater in visually FDG-positive studies compared to visually negative and oncologic negative studies. Among patients with CS, CMA was greater in studies with an EF < 50% (760.3 ± 1,148 vs 87.4 ± 161 g glucose, P = .03) and preceding an adverse clinical event (1,095 ± 1,253 vs 73 ± 144 g glucose, P = .006). CMA was the only independent predictor of events by multivariate analysis. In patients with repeat examinations (n 5 7), CMA decreased with prednisone treatment in 5 of 6 patients. Conclusions: Quantification of FDG uptake in CS correlates with lower EFs, clinical events, and immunosuppression treatment. | - |
dc.description.statementofresponsibility | Azadeh Ahmadian, Ashley Brogan, Jeffrey Berman, Aaron L. Sverdlov, Gustavo Mercier, Michael Mazzini, Praveen Govender, Frederick L. Ruberg, and Edward J. Mille | - |
dc.language.iso | en | - |
dc.publisher | Springer | - |
dc.rights | Copyright © 2014 American Society of Nuclear Cardiology. | - |
dc.source.uri | http://dx.doi.org/10.1007/s12350-014-9901-9 | - |
dc.subject | Metabolism: PET; PET/CT imaging; fluorodeoxyglucose (FDG) | - |
dc.title | Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s12350-014-9901-9 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Sverdlov, A. [0000-0003-2539-8038] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.